SNANF (Sona Nanotech) Short-Term Debt : $0.00 Mil (As of Jan. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Sona Nanotech Short-Term Debt?

Sona Nanotech's Short-Term Debt for the quarter that ended in Jan. 2025 was $0.00 Mil.

Sona Nanotech Short-Term Debt Historical Data

The historical data trend for Sona Nanotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sona Nanotech Short-Term Debt Chart

Sona Nanotech Annual Data

Trend

Oct14

Oct15

Oct16

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Short-Term Debt

Get a 7-Day Free Trial

1.13

0.51

Sona Nanotech Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Sona Nanotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sona Nanotech Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Sona Nanotech's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sona Nanotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sona Nanotech Inc (OTCPK:SNANF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

SONA:Canada

Address

1969 Upper Water Street, Suite 2001, Purdy’s Wharf Tower II, Halifax, NS, CAN, B3J 3R7

Website

https://www.sonanano.com

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and various biomedical applications. The company's product includes Gemini and Saliva tests.